单中心胰腺腺泡细胞癌23例临床诊治分析
DOI:
作者:
作者单位:

南京医科大学第一附属医院、江苏省人民医院胰腺中心

作者简介:

通讯作者:

中图分类号:

基金项目:

江苏省科教能力提升工程(江苏省医学重点学科,ZDXK202222)


Clinical Diagnosis and Treatment of Pancreatic Acinar Cell Carcinoma: A Single-Center Analysis of 23 Cases
Author:
Affiliation:

Fund Project:

Jiangsu Province Capability Improvement Project through Science, Technology and Education (Jiangsu Provincial Medical Key Discipline, ZDXK202222)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    摘要 目的:探讨胰腺腺泡细胞癌(Acinar cell carcinoma,ACC)的临床、影像、病理特点、诊治及预后。 方法:回顾性分析2015年4月至2024年12月本院收治并经病理确诊ACC临床资料,总结其临床表现、影像与病理特点、诊治经过及预后。结果:共计23例ACC入组,男性15例,平均年龄62岁。入院症状腹痛(13例),其他主要症状包括黄疸、腹胀、腰背痛。肿瘤位于胰头15例,胰体尾7例,全胰腺1例。肿瘤平均直径54mm,实性(8例,44.4%),实性伴坏死(5例,27.8%),囊实性(5例,27.8%)。手术:22例行手术切除,1例因第16组淋巴结转移行超声内镜穿刺活检,后综合治疗。单纯腺泡细胞癌(21例),腺泡细胞癌混合导管腺癌(1例),腺泡细胞癌混合神经内分泌肿瘤(1例),淋巴结转移(10例),神经脉管侵犯(20例),R0(切缘)切除(19例)。15例行术后辅助化疗,其化疗方案包括白蛋白紫杉醇和吉西他滨(AG)、吉西他滨和奥沙利铂(Gemox)、替吉奥和奥沙利铂(Sox),吉西他滨和卡培他滨吉(Gemcap),紫杉醇和顺铂(TP),亚叶酸钙、氟尿嘧啶、盐酸伊立替康和奥沙利铂(Folfirinox)。有效随访21例,术后中位生存期26个月,无复发中位生存期15个月,术后1年、3年生存率分别为90.5%,44.4%。术后首次转移复发部位以肝脏(7例)和后腹膜淋巴结(5例)最常见,其次为骨、肺、肠系膜淋巴结及术区局部复发。结论:胰腺腺泡细胞癌(ACC)是一种罕见的恶性肿瘤,临床症状以腹痛为主,肿瘤多呈实性且侵袭性较强(神经脉管侵犯、淋巴结转移常见);手术切除联合术后辅助化疗是主要诊治模式,术后需重点关注肝脏及后腹膜淋巴结以早期识别复发转移。

    Abstract:

    Abstract: Objective: To investigate the clinical, imaging, and pathological characteristics, diagnosis, treatment, and prognosis of pancreatic acinar cell carcinoma (ACC). Methods: A retrospective analysis was conducted on clinical data of patients with pathologically confirmed ACC admitted to our institution from April 2015 to December 2024. The clinical manifestations, imaging and pathological features, diagnosis, treatment, and prognosis were summarized. Results: A total of 23 ACC patients were enrolled, including 15 males, with a mean age of 62 years. The most common presenting symptom was abdominal pain (13 cases), followed by jaundice, abdominal distension, and back pain. Tumors were located in the pancreatic head (15 cases), pancreatic body/tail (7 cases), and diffusely involved the entire pancreas (1 case). The mean tumor diameter was 54 mm. Tumors presented as solid (8 cases, 44.4%), solid with necrosis (5 cases, 27.8%), or cystic-solid (5 cases, 27.8%). Surgical resection was performed in 22 cases, while one patient underwent endoscopic ultrasound-guided biopsy due to metastasis to the №16 lymph node group and received comprehensive therapy. Pathologically, 21 cases were pure ACC, one case was mixed with ductal adenocarcinoma, and one case was mixed with neuroendocrine tumor. Lymph node metastasis was observed in 10 cases, and neurovascular invasion was present in 20 cases. R0 resection was achieved in 19 cases. Postoperative adjuvant chemotherapy was administered to 15 patients, with regimens including nab-paclitaxel plus gemcitabine (AG), gemcitabine plus oxaliplatin (Gemox), tegafur-gimeracil-oteracil potassium plus oxaliplatin (SOX), gemcitabine plus capecitabine (Gemcap), paclitaxel plus cisplatin (TP), and FOLFIRINOX. Among 21 patients with effective follow-up, the median overall survival was 26 months, and the median recurrence-free survival was 15 months. The 1-year and 3-year survival rates were 90.5% and 44.4%, respectively. The most common sites of initial recurrence were the liver (7 cases) and retroperitoneal lymph nodes (5 cases), followed by bone, lung, mesenteric lymph nodes, and local recurrence. Conclusion: Pancreatic acinar cell carcinoma is a rare malignant tumor characterized mainly by abdominal pain, often presenting as a solid mass with aggressive features such as frequent neurovascular invasion and lymph node metastasis. Surgical resection combined with adjuvant chemotherapy is the main treatment approach. Postoperative surveillance should focus on the liver and retroperitoneal lymph nodes for early detection of recurrence and metastasis.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2025-08-08
  • 最后修改日期:2025-09-03
  • 录用日期:2025-10-29
  • 在线发布日期:
  • 出版日期:
关闭